Jaroslaw P. Maciejewski, MD, PhD, FACP, is Staff Physician in the Cleveland Clinic Department of Hematologic Oncology and Blood Disorders and is board certified in hematology and internal medicine. He is also Chairman of the Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute and has an academic rank of Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Recognized for his scholarly achievement in biomedical research, Dr. Maciejewski is an elected member of The American Society for Clinical Investigation (ASCI).
His clinical areas of expertise include bone marrow failure syndromes (including aplastic anemia, myelodysplastic syndrome, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria), and myeloid malignancies. His research deals with the molecular pathogenesis of these disorders and deals with various specific aspects of stem cell biology, genetics, cytogenetics and immunobiology. He has developed multiple whole genome scanning technologies for laboratory and diagnostic use, including SNP-arrays, methylation arrays and viral chips.
Dr. Maciejewski attended medical school at the Medical School Charite, Humboldt University, Berlin, Germany receiving his medical degree and doctorate from the Institute for Medical Immunology at Humboldt University Medical School. He completed his internal medicine residency at the University of Nevada, School of Medicine in Reno, NV and Hematology Fellowship at the National Institutes of Health Medical Center, Bethesda, MD. He also completed his postdoctoral research fellowship at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, MD where he later served as Staff Scientist before joining Cleveland Clinic in 2001 as Staff Physician and Section Head of Experimental Hematology. In January 2009, Dr. Maciejewski was appointed Chairman of the newly created Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute.
Dr. Maciejewski has a distinguished track record in research relating to the hematology and pathophysiology of hematologic diseases including bone marrow failure syndromes (BMFS). His extensive list of publications (over 150 peer-reviewed journal articles and book chapters) demonstrates his success as an accomplished translational physician-scientist. As Principal Investigator, Dr. Maciejewski has acquired notable grant funding from federal, foundation and industry sponsors since joining Cleveland Clinic in 2001. His most recent achievement is a $1.9 million grant award from the National Institutes of Health’s Transformative R01 program. The Transformative R01 grants are awarded for "exceptionally innovative, high-risk and unconventional research projects that have the potential to create or overturn fundamental paradigms.” This funding will help support Dr. Maciejewski’s research related to whether viruses could be the cause of certain types of bone marrow cancers and other blood disorders. In addition to bench translational research, he leads the Cleveland Clinic Bone Marrow Failure Program that conducts various clinical trials based on investigator-initiated protocols involving the application of targeted immune therapies.
He serves on the Medical Advisory Board of the International Aplastic Anemia and Myelodysplastic Syndrome Foundation, the editorial board of Blood and has also been a reviewer on various study sections for the NIH. He served on the International Scientific Committee at the 10th International Symposium on Myelodysplastic Syndromes held in Patras, Greece in 2009 and was presented with the Celgene Young Investigator Award for Clinical Research in Hematology at the 50th Annual ASH Meeting in San Francisco in 2008. Dr. Maciejewski is also committed to his role as mentor. His K24 Career Development award from the NIH has enabled him to actively continue mentoring medical students, postdoctoral/clinical fellows and junior faculty through his Bone Marrow Failure Training Program for physician-scientists.